Human Platelet Lysate Market Research Report 2020 (Includes Business Impact of COVID-19) By Product Type (Heparin-free Platelet Lysate and Platelet Lysate with Heparin), By Application (Research Use and Clinical Use)

                                          
"The ongoing Coronavirus (COVID-19) pandemic is re-shaping everything from global economies to product categories, pricing, and stock availability to the consumer behavior. The final report is updated to address the impact of COVID-19 on the Human Platelet Lysate market.

Trusted Business Insights is tracking mining/oil and gas, transportation, employment services, travel arrangements, and leisure and hospitality sector closely as they are likely to be the hardest-hit sectors. Utilities, local pharma, diagnostics, consumer goods and durables, agro chem and fertilizers, and telecommunications are the sectors that will be weathering the COVID-19 storm and most likely come out relatively unscathed. Interdependencies of sectors are factored in our research report on the Human Platelet Lysate market."

Human platelet lysate (HPL) is a non-animal derived cell culture growth supplement obtained from blood platelets after freezing and thawing. HPL contains abundant growth factors and cytokines necessary for cell growth and proliferation. Platelet lysate can be used as a source of growth factors to replace bovine serum in the cell culture medium. Replacing bovine serum with HPL allows expansion and clinical grade production of functional mesenchymal stromal cells by removing the risk of xenogeneic immune reactions and transmission of bovine prion and viral pathogens.

The global Human Platelet Lysate market is valued at 129.34 million US$ in 2017 growing at a CAGR of 26.8% during 2019-2025.

The demand of Human Platelet Lysate for Clinical applications accounted for US$87.51 Mn of total market value in 2017.

Snapshot of Porter’s Five Forces Analysis for the current Human Platelet Lysate market.

 



Supplier Power: High
The Threat of Substitution: Low
Competitive Rivalry: Moderate


A limited number of suppliers that can meet
the high-quality standards set for human
platelet lysate manufacturing
Prices of human platelet lysate are
expected to be stable hence fewer chances
of getting substituted
The degree of competition is
moderate as the manufacturers are
offering similar product categories
with limited differentiating
attributes. Many of the market
players are looking for their own
arrangements of raw materials. This
may lead to reduced pricing
pressure during the forecast period.


Buyer Power: Low
The Threat of New Entry: Medium


A limited number of human platelet lysate
manufacturers have the ability to meet high
degree of customization requirements of the
large buyers
Rising demand for human platelet lysate
products across both developed and
developing countries



Top Level Analysis of Human Platelet Lysate Market:

 	
The US FDA is moving towards adopting European guidelines requiring that bovine materials be removed from culturing media for any therapeutic product containing cultured cells, thus making human platelet lysate an attractive alternative to the production and manufacturing processes which is anticipated to fuel the demand of human platelet lysate during the forecast period.
 	
Traditionally, the fetal bovine serum is supplemented in basic research and in most clinical trials. Within the past years, many laboratories adapted their culture conditions to human platelet lysate (hPL), which further stimulates the proliferation and expansion of MSCs. Particularly with regard to clinical application, human alternatives

In 2016, the market size of the Heparin-free Platelet Lysate market was USD $45.96 Million and the market size of Platelet Lysate with Heparin was USD $47.76 Million with a total market value of USD $93.72 Million. Clinical application and Research Application accounted for USD $63.56 Million and USD $30.16 Million respectively.

Additionally, in terms of volume(liters), Heparin-free Platelet Lysate market demand was of 19512 liters, approximately 5154 US gallons and that of Platelet Lysate with Heparin was 20445 liters, approximately 5400 US Gallons (Total of 39957 liters, 10554 US Gallon)

North America Human Platelet Lysate market accounted for 44% of market share, followed by Europe at 26%. APAC, Latin America, Middle East, and Africa Human platelet size was 19%, 6%, and 5% respectively.

Bifurcation of demand by End-User Industries

 



Contract Research Organizations
Biopharmaceutical Companies
Academic & Research Institutes
Cell Therapy Manufacturers
Total


31.26
24.74
19.55
18.18
93.73 (USD Million)


12,629
9,997
7,898
7,343
37867 (Litres)



 

This report focuses on Human Platelet Lysate volume and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Human Platelet Lysate market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, China, and Japan.

This market research study provides detailed qualitative and quantitative analyses of the global Human Platelet Lysate Market. Additionally, the report provides a comprehensive review of the major market drivers, restraints, opportunities in the global Human Platelet Lysate Market.

At the company level, this report focuses on the production capacity, ex-factory price, revenue, and market share for each manufacturer covered in this report.

The following manufacturers of Platelet Lysate are covered (Click to visit respective product offering page)

 	
Mill Creek Life Sciences
 	
Merck & Co., Inc
 	
STEMCELL Technologies Inc
 	
AventaCell BioMedical
 	
Compass Biomedical, Inc
 	
Macopharma SA
 	
Trinova Biochem GmbH
 	
PL BioScience GmbH
 	
Cook Regentec
 	
Cambium Medical Technologies
 	
Life Science Group
 	
Zen-Bio, Inc.

Segment by Regions

 	
North America
 	
APAC
 	
EMEA
 	
LATAM

Segment by Type

 	
Heparin
 	
Heparin free

Segment by Application

 	
Biopharmaceutical companies
 	
Contract research organizations
 	
Academic & research institutes
 	
Pharmaceutical companies
 	
Others